2024-09-02 - Analysis Report
## Gilead Sciences, Inc. (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences, Inc. is a biopharmaceutical company focused on the development and commercialization of life-saving therapies.

**1. Performance Comparison:**

* **Cumulative Return:** GILD's cumulative return is 14.51%, significantly lagging behind the S&P 500 (VOO) which has a cumulative return of 89.66%.
* **Relative Deviation:** The relative deviation of GILD's performance compared to VOO is -75.15, indicating that GILD has underperformed VOO significantly. This means that GILD's performance is currently at the 15.83 percentile of its historical performance range relative to VOO.

**2. Recent Price Movement:**

* **Closing Price:** $79.0
* **5-day Moving Average:** $78.19
* **20-day Moving Average:** $75.47
* **60-day Moving Average:** $71.78

The recent price action indicates a short-term bullish sentiment. GILD is currently trading above all three moving averages, suggesting a potential upward trend.

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 87.42, indicating the stock is currently in overbought territory. 
* **PPO (Percentage Price Oscillator):** 0.4, suggesting a strong momentum in the stock price.
* **Delta_Previous_Relative_Divergence:** -5.9, suggesting a recent short-term bearish trend.
* **Expected Return:** 21.27%, indicating a potential 5-year expected return on investment. 

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

The most recent earnings report for Q2 2024 showed an EPS of $1.29, exceeding analyst expectations. Revenue also came in at $6.95B, surpassing analyst estimates. This indicates a positive trend in GILD's earnings performance.

**5. Overall Analysis:**

GILD's stock has underperformed the market significantly in the long term, but recent earnings and price action suggest a potential upward trend.  The technical indicators show conflicting signals, with the RSI indicating overbought conditions while the PPO shows strong momentum. The most recent earnings report exceeded expectations, suggesting a positive outlook for the company. However, the short-term relative divergence suggests caution. 

**6. Conclusion:**

GILD's stock presents a mixed picture. While recent earnings have been positive and the price action suggests a short-term uptrend, the long-term underperformance and technical overbought signals warrant caution. Investors should carefully consider their investment strategy and risk tolerance before investing in GILD. 
